Advaxis Chief Executive Officer to Present at the 10th Annual World Vaccine Congress.

Presentations to Address Challenges Facing Biotech Companies and the use of Bacterial Vectors for The Treatment of Cancer

Conference to be Held October 6-9, 2008, at Le Palais des Congres de Lyon, France

NEW BRUNSWICK, N.J. -- Advaxis Incorporated (OTCBB: ADXS) Chairman and CEO Tom Moore will present at this year's World Vaccine Congress 2008, being hosted at Le Palais des Congres de Lyon in Lyon, France. The Conference will be held October 6 - 9, 2008.

Mr. Moore will address the World Vaccine Congress on the funding challenges facing biotech financings on Monday, October 6th and will discuss the unique attributes of live Listeria vaccines for the treatment of cancer on Tuesday, October 7th.

He will also provide an update on the Phase 1 of Lovaxin C trial in recurrent cervical cancer, including the latest survival data. Mr. Moore will also discuss recent information on some of newly discovered mechanisms of action that may explain why live Listeria vaccines are so effective, and support why these agents may play an increasingly important role in the clinic.

For more information: http://www.terrapinn.com/2008/wvcl/programme.stm

About The World Vaccine Congress Lyon 2008

With over 120 individual companies already sending individual and multiple representatives, World Vaccine Congress Lyon is the largest gathering of European vaccine industry professionals this year.

About Lovaxin C Vaccine

Advaxis' Listeria technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Bioengineered Listeria that are attenuated and secrete Advaxis' proprietary fusion proteins have the ability to generate a robust immune response, break immune tolerance to cancer and produce an unusually strong and effective multi-level therapeutic immune response to existing cancer and other diseases.

Advaxis' Listeria-based technology is based on over a decade's worth of work by Dr. Yvonne Paterson in her laboratory at the University of Pennsylvania. The Company's proprietary antigen fusion protein technology, stimulates innate immunity, both arms of the adaptive cellular immune system, suppresses regulatory T cells that inhibit many vaccines in the function of activated tumor-killing cells and has other anti-tumor effects.

Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets human papilloma virus (HPV)-associated cancers such as cervical and head and neck. Current Lm vaccines in development target prostate, breast, ovarian and other cancers. Recently, Advaxis completed a Phase I clinical trial of Lovaxin C. A Phase II clinical trial is planned for patients with cervical intraepithelial neoplasia (CIN). The Company intends to start this study in CIN 2/3 patients in the fall of 2008.

Unlike prophylactic vaccines, Lovaxin C was designed to treat women who have already developed cervical cancer as a result of contracting a human papilloma virus (HPV) infection, which is the most prevalent sexually transmitted disease in the US. Current products on the market are ineffective in treating HPV-infected women.

For further information on Lovaxin C, please visit: http://www.advaxis.com/lc.htm

About Advaxis, Inc.

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes ("Lm") cancer vaccines based on technology developed by Dr. Yvonne Paterson, Professor of Microbiology at the University of Pennsylvania and Chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms and which has been safely administered to patients with cancer.

Aside from Lovaxin C, Advaxis has agents in development for prostate, breast, and other cancer types, and is currently re-engineering Listeria to make it a better vaccine vehicle.

For further information on the Company, please visit: http://www.advaxis.com.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance, or achievements.